Circassia to Sell Own Cat-Allergy Vaccine If Test Works

Imperial Innovations Group Plc will help Circassia Holdings Ltd., in which it holds a 20 percent stake, commercialize a cat-allergy vaccine if it clears final-stage trials even as would-be suitors target the company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.